EMEA-001638-PIP02-21
Key facts
Invented name |
Tecentriq
|
Active substance |
atezolizumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0384/2021
|
PIP number |
EMEA-001638-PIP02-21
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms and melanoma)
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Roche Registration GmbH
E-mail: global.paediatrics@roche.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|